At ECR 2026, Dominik Guenzel, Chief Business Officer at Lunit, discussed how the company’s more than decade-long presence in medical imaging AI has helped shape the evolving landscape of clinical AI solutions.
According to Guenzel, Lunit’s long history in the field has enabled the company to build strong networks with healthcare providers and refine its algorithms based on real clinical needs. Over time, he said, the company’s solutions have increasingly adapted to the workflows and expectations of radiologists.
Lunit has also focused heavily on building clinical evidence for its AI technologies. Guenzel noted that many independent research groups and academic institutions are evaluating the company’s tools, particularly in breast imaging. While Lunit supports these collaborations, clinicians and researchers typically design and interpret the studies themselves, providing independent validation of the technology.
Looking ahead, Guenzel expects the AI imaging market to see both continued innovation and consolidation over the coming years. While some companies may join larger platforms or technology providers, he believes several specialized AI developers will continue to grow and differentiate themselves through strong performance, trusted partnerships, and reliable clinical support.
